If you have suffered a loss in excess of $100,000 from investment in Synergy securities purchased on or after September 5, 2017 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at email@example.com or by telephone at (410) 415-6616.Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) ("Synergy" or the "Company") securities during the period between September 5, 2017 and November 14, 2017, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until April 10, 2018 to seek appointment as lead plaintiff. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Synergy securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that the loan from CRG Partners III L.P. ("CRG Loan") did not fund Synergy's operations through 2019, that the Company could not access the second tranche of $100 million financing on or before February 28, 2018 without issuing dilutive equity, and that the Company could not access the third tranche of the CRG Loan if and when needed because terms were required to be met in order to access those tranches. According to the complaint, following a November 9, 2017 disclosure of the true terms of the CRG Loan and their effect upon Synergy's financial condition, the value of Synergy shares declined significantly.